Enliven Therapeutics, Inc. (ELVN)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing
Enliven Therapeutics is positioned as a late-stage, well-capitalized biotech with $895M cash, funding operations into 2030 and the pivotal ENABLE-2 trial. ELVN-001 targets chronic myeloid leukemia as a selective ATP-competitive inhibitor, aiming for a differentiated, chronic-use profile in a sequential treatment paradigm. Phase 1 data show 61% MMR at 80 mg daily, with favorable safety and convenience for chronic administration, supporting potential in earlier-line CML settings.
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
Enliven Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 41 | $1,301.13 | $1,610.48 | $309.35 | 23.78% |
| NA Nizar Araji National Bank Of Canada /FI/ | 7 | $355.95 | $275.31 | -$80.64 | -22.65% |
| BG Bart Gancher Intech Investment Management LLC | 12,090 | $287,359.68 | $475,499.7 | $188,140.02 | 65.47% |
 John H. Burbank III Passport Capital LLC | 905,191 | $29.28M | $36.04M | $6.77M | 23.12% |
| CD Charlie Durham Sterling Capital Management LLC | 150 | $2,310.22 | $5,892 | $3,581.78 | 155.04% |
Enliven Therapeutics, Inc. (ELVN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Enliven Therapeutics, Inc. ever had a stock split?
Enliven Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Richard A. Fair CEO | NASDAQ (NGS) Exchange | 29337E102 CUSIP |
| US Country | 67 Employees | - Last Dividend | 24 Feb 2023 Last Split | 12 Mar 2020 IPO Date |
Overview
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is distinguished by its dedicated pursuit of creating innovative small molecule inhibitors aimed at contributing significantly to cancer treatment. With its central operations based in Boulder, Colorado, Enliven Therapeutics has embarked on a mission to transform the therapeutic landscape for patients bearing the burden of cancer. Through its focused research and development efforts, the company is at the forefront of advancing potential treatment options into clinical evaluation, demonstrating its commitment to addressing the unmet needs within the oncology domain.
Products and Services
Enliven Therapeutics, Inc. is progressively shaping the field of oncology with its notable product candidates, each tailored to target specific cancer types with precision. The following are the cornerstone developments in their portfolio:
- ELVN-001: This pioneering therapy is currently under assessment in a Phase 1 clinical trial, designed to offer a new horizon of treatment for adults diagnosed with chronic myeloid leukemia (CML). ELVN-001 represents Enliven Therapeutics' commitment to tackling hematologic malignancies with novel, targeted therapeutic options.
- ELVN-002: In a stride towards addressing solid tumors, ELVN-002 is another vital component of the company's innovative pipeline. Undergoing a Phase 1 clinical trial in adults, this molecule is particularly focused on solid tumors that present HER2 alterations. This aligns with the company's strategy to expand its therapeutic reach by developing targeted treatments for a broader spectrum of cancers.
Contact Information
